Session

24.03.2021     14:35–17:05

Title:
Plenary session 2
SARS-CoV-2 – Vaccines and neutralising abs
Type:
Plenary session

24.03.2021
14:35–17:05

Title:
Plenary session 2
SARS-CoV-2 – Vaccines and neutralising abs
Type:
Plenary session


14:35–15:00
Developing an mRNA Vaccine against SARS-CoV2 in Lightspeed
Özlem Türeci (Mainz/DE)
Talk time: 20 + 5 min


15:00–15:25
PT 6 Rapid response to SARS-CoV-2 enabled by mRNA technology
Darin Edwards (Cambridge, MA/US)
Talk time: 20 + 5 min


15:25–15:50
PT 7 Development of ChAdOx1 nCoV-19
Sarah Gilbert (Oxford/GB)
Talk time: 20 + 5 min


15:50–16:15
Janssen’s efforts in the development of a COVID-19 Vaccine
Roland Zahn (Leiden/NL)
Talk time: 20 + 5 min


16:15–16:40
PT 9 The DZIF COVID-19 candidate vaccine MVA-SARS-2-S
Gerd Sutter (München/DE)
Talk time: 20 + 5 min


16:40–17:05
PT 10 Antibody-mediated SARS-CoV-2 Neutralization
Florian Klein (Köln/DE)
Talk time: 20 + 5 min